The outcomes of patients with unresected anaplastic thyroid carcinoma (ATC) from the National Cancer Data Base (NCDB) were assessed, and potential correlations were explored between radiation therapy (RT) dose and overall survival (OS). METHODS: The study cohort was comprised of patients who underwent either no surgery or grossly incomplete resection. Correlates of OS were explored using univariate analysis and multivariable analysis (MVA). RESULTS: In total, 1288 patients were analyzed. The mean patient age was 70.2 years, 59.7% of patients were women, and 47.6% received neck RT. The median OS was 2.27 months, and 11% of patients remained alive at 1 year. A positive RT dose-survival correlation was observed for the entire study cohort, for those who received systemic therapy, and for those with stage IVA/IVB and IVC disease. On MVA, older age (hazard ratio [HR], 1.317; 95% confidence interval [CI], 1.137-1.526), 1 comorbidity (HR, 1.587; 95% CI, 1.379-1.827), distant metastasis (HR, 1.385; 95% CI, 1.216-1.578), receipt of systemic therapy (HR, 0.637; 95% CI, 0.547-0.742), and receipt of RT compared with no RT (<45 grays [Gy]:HR, 0.843; 95% CI, 0.718-0.988; 45-59.9 Gy: HR, 0.596; 95% CI, 0.479-0.743; 60-75 Gy: HR, 0.419; 95% CI, 0.339-0.517) correlated with OS. The RT dose-survival correlation for patients who received higher (60-75 Gy) versus lower (45-59.9 Gy) therapeutic doses was confirmed by propensity-score matching. CONCLUSIONS: Survival was poor in this cohort of patients with unresected ATC, and more effective therapies are needed. However, the association of RT dose with OS highlights the importance of identifying patients with unresected ATC who may still yet benefit from multimodal locoregional treatment that incorporates higher dose RT. Cancer 2017;123:1653-61.
INTRODUCTION
Anaplastic thyroid carcinoma (ATC) is one of the most aggressive malignancies of the head and neck. Although numerically rare, comprising from 1% to 2% of all thyroid cancers, it has a grim prognosis, because ATC accounts for approximately 40% of all thyroid cancer-related deaths. [1] [2] [3] Median survival ranges from 3 months to 10 months, with long-term survival rates of <20%, because patients routinely present with advanced disease. 4, 5 Patients with ATC often present with rapidly growing and immediately threatening local tumor that is not amenable to meaningful resection. To date, there still are no standard, highly effective treatment regimens for ATC, but treatment is generally multimodal. [6] [7] [8] Fit patients who present without sign of distant metastases are evaluated for surgery and adjuvant therapy to provide the best chance for a favorable outcome. However, because complete surgical resection is rarely feasible in ATC, radiation therapy (RT), often with concurrent chemotherapy, is considered in an attempt to induce local tumor regression (and achieve interim local control) and to avoid or delay local progression, preventing or deferring airway obstruction, severe dysphagia, and/or death secondary to overwhelming local tumor burden: scenarios that unfortunately are common in these patients despite prompt tracheostomy. [9] [10] [11] [12] [13] Because presentation with or development of subsequent distant metastases is also common, clinicians are faced with the challenge of how to prioritize local therapies and their intent or aggressiveness. [14] [15] [16] At our center, the presence of distant metastases does not necessarily preclude the use of upfront, locally palliative therapy to either treat or prevent impending symptoms or death from tracheal or esophageal compromise, because medically fit patients with smaller volume distant disease may still benefit from more durable local tumor control through the receipt of RT.
Despite the poor overall prognosis of patients with unresected/unresectable local or distant metastatic disease and the palliative nature of treatment in these scenarios, we hypothesize that those treatment regimens incorporating higher doses of neck RT may at least delay local tumor progression and thus translate into improved patient survival, given the rapidity of mortality for those with progressive disease. Because of the rarity of this disease and thus the inability of any single center (even a high-volume tertiary center) to accrue sufficient numbers of patients for statistical validity, we evaluated the survival of patients with unresected ATC within the National Cancer Data Base (NCDB).
The specific objectives of the current study are: 1) to characterize survival outcomes for patients with unresected ATC (ie, those who either underwent no surgery or underwent grossly incomplete resection); 2) to explore patient-specific, tumor-specific, and treatment-specific correlates of overall survival (OS); and 3) to assess RT dose-survival correlation and define clinical subgroups of interest for future analyses
MATERIALS AND METHODS

Data Set
The NCDB is a joint program of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The NCDB, established in 1989, is a nationwide, facility-based, comprehensive clinical surveillance resource oncology data set that captures 70% of all newly diagnosed malignancies in the United States annually, including 92% of all thyroid cancers. 17 These patients come from approximately 1500 Commission on Cancer-accredited cancer programs. The NCDB is the world's largest oncology outcomes database and contains over 30 million historical records. The data used in the current study were derived from a de-identified NCDB file. Access to this Health Insurance Portability and Accountability Act (HIPAA)-compliant data was provided to one of the authors (C.M.P.) as part of the NCDB Participant Use File program.
Clinical variables of patients with ATC reported to the NCDB from 1998 to 2012 were retrieved from the NCDB using the International Classification of Disease, third edition (ICD-O-3) code 8021/3. Patients who were diagnosed after 2011 were excluded because of the lack of available survival data at the time of data extraction for this analysis. Because the objective of this study was to focus on patients who had ATC with locally advanced or unresected/unresectable tumors, patients with tumors measuring <1 cm and those who underwent complete surgical resection of macroscopic disease (classified as either an R0 or R1 resection) were excluded. Those who had gross residual tumor after attempted surgery (classified as an R2 resection) or who did not undergo surgery were included.
Specific data examined included patient age at diagnosis; sex; race/ethnicity; the presence of comorbidities; tumor size; lymph node involvement; evidence of distant metastasis; American Joint Committee on Cancer tumor, lymph node, metastasis (TNM) category and stage grouping; type of surgery performed; surgical margin status; receipt of chemotherapy as part of the first course of treatment; and patient survival. The RT details collected were treatment site, modality, dose, number of fractions, overall treatment time, and interval from surgery to the start of RT. Details regarding the types of systemic therapy received and patterns of disease recurrence (local, regional, or distant relapse) are not available within the NCDB.
OS was compared by patient, tumor, and treatment groups of interest, including by neck RT dose. To explore the neck RT dose-survival correlation, patients who received from 60 to 75 grays (Gy) were considered to have received a higher therapeutic dose, and those who received from 45 to 59.9 Gy had received a lower, potentially therapeutic dose. Those who received < 45 Gy were considered to have received palliative-intent RT and are described here for completeness. Those who received > 75 Gy were excluded from survival comparison analyses because they were considered to have received doses beyond the usual therapeutic range for this disease and anatomic site.
Statistical Analysis
Analyses of variance and Pearson chi-square tests were used for continuous and categorical data, respectively. The median follow-up for surviving patients was calculated using the reverse Kaplan-Meier estimate method.
Survival curves were generated using the Kaplan-Meier product-limit method and were compared using the logrank test. Time-to-event was indexed to the date of diagnosis. Correlates of OS were explored using univariate and multivariable analyses (MVA) with a Cox proportional-hazards approach for nonmatched comparisons. Propensity-score matching was subsequently performed using a 1:1 nearest-neighbor method without replacement for patients who received higher versus lower therapeutic doses of neck RT. 18 Balance was assessed using mean standardized differences. Univariate Weibull parametric survival analysis using the propensity-match score as a stratifier was implemented to calculate the b-coefficient and hazard ratio (HR) of death as a function of RT dose. Propensity score-adjusted P values < .05 were considered significant. Analyses were performed using SPSS version 23.0 (IBM Corporation, Armonk, NY).
RESULTS
Patients
Of the 355,028 patients with thyroid malignancies registered in the NCDB from 1998 to 2012, 3266 (0.92%) were ATC. Of these, 2987 ATCs were diagnosed between 1998 and 2011 and also measured 1 cm in size, and 1727 of patients with these tumors either did not undergo any surgery or underwent grossly incomplete (R2) surgical resection. Of those patients, 439 were excluded (202 for having no documented RT target, 110 for having a distant RT target, and 127 for incomplete RT dose information). The most common distant RT targets were documented as other, not otherwise specified; lung/chest; and brain. The 1288 remaining patients who had received either documented RT to the neck or no RT comprised the final study cohort. Of these, 674 patients (52.3%) received no neck RT, 294 (22.8%) received RT at < 45 Gy, 134 (10.4%) received from 45 to 59.9 Gy, 178 (13.8%) received from 60 to 75 Gy, and 8 (0.6%) received > 75 Gy (Fig. 1) . Of the 614 patients who received RT, details regarding the dose per fraction were available for 544 (88.6%); and, of these, 80 (14.7%) received 1.5 Gy per fraction, which is a dose per fraction commonly used in hyperfractionation schedules. However, details of the RT fractionation schedules are not specifically recorded in the NCDB.
Patient, tumor, and treatment characteristics according to neck RT dose group are listed in Table 1 . For the study cohort, treatment was provided at 627 unique institutions. The mean number of patients treated per institution over the study period was 2.0, and the maximum at any single facility was 21 patients. Overall, 47.2% of patients had distant metastases at the time of diagnosis, 45.8% had regional lymph node involvement (N1), and 52.6% had T4b tumors. When considering the neck RT groups of interest, the group that received from 45 to 59.9 Figure 1 . Study cohort selection from the National Cancer Data Base (NCDB) from 1998 to 2012 is illustrated. Individuals represented in the dashed red box were excluded from the study. ATC indicates anaplastic thyroid carcinoma; Gy, grays; RT, radiation therapy; unk., unknown.
Gy, compared with the group that received from 60 to 75 Gy, was no different in mean age, sex, ethnicity, comorbidities, mean tumor size, lymph node involvement, receipt of surgery, or receipt systemic therapy; but patients in the former group were more likely to have had distant metastasis at diagnosis (48% vs 34%; P 5 .011) and less likely to have received intensity-modulated RT technique (43.8% vs 27.6%; P 5 .003). Of the 674 patients who received no neck RT, 582 (84%) also received no systemic therapy.
Survival Analyses
The median follow-up for surviving patients was 5.5 years. The median survival ( 6 standard error [SE]) for the cohort overall was 2.27 6 0.102 months, with 11.29% and 6.55% of patients alive at 1 and 2 years, respectively (Supporting Fig. 1 ; see online supporting information). The survival curves by neck RT group for the study cohort overall, for those who received systemic therapy, and for those with stage IVA/IVB and IVC disease are provided in Figure 2 . A positive dose-survival correlation was demonstrated for each aforementioned group of interest in this univariate analysis, although differences for those with stage IVC disease were small. For patients who received systemic therapy and RT and for those with stage IVA/IVB disease, visible separation in the tail region of the curve illustrates extended survival in the higher RT dose group, with a relative plateau of the curve after 2 years. For the cohort overall, the median survival (6SE) was 1.31 6 0.08 months for those who did not receive neck RT, 1.97 6 0.127 months for the group that received from 1 to 44.9 Gy, 4.240 6 0.355 months for the group that received from 45 to 59.9 Gy, and 6.77 6 0.391 for those who received from 60 to 75 Gy.
Correlates of Survival
Results from the univariate and multivariable analyses are provided in Table 2 . The variables included in the multivariable model were those that were statistically significant on univariate analysis or were established as clinically important prognostic factors. The only variable included in the MVA that was not statistically significant on univariate testing was the presence of lymph node metastases, which is an established American Joint Committee on Cancer staging variable. On MVA, advanced age (HR, To further explore the neck RT dose-survival correlation and to reduce the influence of patient selection bias and other confounding factors, propensity score matching was performed on the 312 patients who received neck RT within the specified therapeutic range (45-75 Gy). They were matched using propensity scores according to age, sex, tumor (T)-classification, presence of lymph node involvement, presence of metastasis at diagnosis, receipt of systemic therapy, and receipt of R2 surgery. The treatment group comprised those patients who received a higher therapeutic dose (60-75 Gy; n 5 178), and the control group comprised those who received a lower, potentially therapeutic dose (45-59.9 Gy; n 5 134). Eventually, 125 patients in each RT dose cohort were matched successfully. Balance between variables in both cohorts is demonstrated in Supporting Table 1 (see online supporting information). Patients who received from 60 to 75 Gy had significantly better OS compared with patients who received from 45 to 59.9 Gy (31% vs 16% at 1 year; stratified log-rank P 5 .008) (Fig. 3) . Univariate Weibull parametric survival analysis using the propensity-matched score as a stratifier demonstrated that patients who received lower dose RT had a higher risk of death compared with those who received higher dose RT (b-coefficient, 1.16; 95% CI, 1.02-1.30 [equivalent to an HR of 1.2; 95% CI 1.02-1.54]; P 5 .027).
DISCUSSION
Patients with unresected/unresectable ATC remain a significant challenge for clinicians in part because of extremely aggressive locoregional behavior and frequent synchronous or rapid development of distant metastases, resulting in unsatisfying survival and often unsuccessful palliative efforts. In this large-scale, multisite data set, we observed that the survival of patients with unresected ATC within the NCDB was poor, as expected. Nonetheless, patients who received treatment that incorporated higher dose RT to the neck had incontrovertibly extended survival, although it remains unclear whether, as we suspect, this is potentially because of more durable local tumor control or uncollected confounders that were hidden within this large-scale registry. This dose-survival correlation was maintained when we restricted the comparison to only those who were selected to receive more than traditional palliative doses of neck RT (45 Gy), suggesting that this was not likely to present a discrimination between dose as a surrogate short-course temporizing palliative RT (eg, the classic 30 Gy in 10 fraction or quad-shot 14 Gy in 4 fraction regimens routinely used for pain control without expectation of local response). 19 To better isolate a potential dose-survival correlation, we elected to compare these 2 groups using propensity-score matching with the hypothesis that, accounting for differentials in other variables, patients who received treatment in the lower dose range also could have been candidates for higher dose RT.
Regarding the patterns of care observed, within the unresected/unresectable cohort, the majority of patients did not receive any neck RT; and, within in the no neck RT group, only approximately 14% received any systemic therapy. This, coupled with the strikingly short median survival in the no neck RT group (<2 months), suggests that these patients may have been judged as either unfit for or unlikely to benefit from any cancer-directed therapy. Of those who did receive neck RT, 49% received what would be considered nontherapeutic (eg, pain reduction/ palliative) doses of RT (<45 Gy), and the observed median survival in this group was also <2 months. Overall, only 24% received RT to the neck at a dose specified as within in the usual therapeutic range (45-75 Gy), suggesting that a minority of patients are being selected for more definitive RT schedules and pointing to the utility of population-level databases like the NCDB to benchmark patterns of care and outcomes in a group so rare that neither institutional nor cooperative group studies will likely provide level 1 evidentiary guidance. Alternatively, this finding also points to a potential window for improved outcomes with more routine incorporation of RT, a widely available therapy that may currently be underused in this population. Glaser et al recently queried the NCDB for all patients with ATC and noted an association between survival and the following features: absence of lymph node metastases, no distant metastasis, tumors 6 cm, R0 resection, total thyroidectomy, and receipt of high-dose RT (>59.4 Gy). 20 The observation of an association between comparatively longer survival and complete surgery and higher dose RT is consistent with multiple singleinstitutional series. [21] [22] [23] [24] Unfortunately, according to Glasser et al, only 13% of patients with ATC in the NCDB underwent R0 resection, and only approximately 22% received higher dose neck RT, suggesting that a limited minority were (and are) selected or eligible for more aggressive local therapy approaches, which is also supported by our results.
The current study focused on a single intact disease cohort specifically to assess dose-response data in the NCDB in an effort to restrict the potential confounding effects of surgical therapy. Thus, the observation of substantively improved survival in a cohort with intact disease suggests that, rather than having intractable tumors with no indication for local therapy, in fact, these patients are potential candidates even in scenarios for which complete resection is not an availed option. In addition, a statistically significant dose-survival relation was also maintained, albeit of small magnitude, even for patients with distant metastatic disease (stage IVC), suggesting that a competing risk of death from local and distant metastatic progression might be altered by sufficient local therapy. Similar to the study by Glaser et al, we identified multiple patient, disease, and treatment characteristics that were correlated with survival in patients with ATC. Taken together, the results from Glaser et al and our current study may help inform clinicians regarding who might benefit most from therapy and points out the need to evaluate patients for RT at therapeutic doses not only postoperatively but also in fit patients with unresectable disease.
Like any large-scale database, the standard caveats apply regarding data quality and generalizability. 25 For example, any palliative benefit of RT or other treatments received could not be quantified, and toxicity data are not directly available within the NCDB. Given that most patients with ATC have incurable disease, the preservation of quality of life and side effects of available therapies must be carefully balanced are veiled in this data set. Although the NCDB represents the largest repository of data on patients with ATC and thus is a reasonable and justifiable approximation of the national outcomes for this disease, the incidence of tracheostomy, RT fractionation scheme, planned versus delivered RT dose, patient performance status, time from symptoms to diagnosis, clinical tumor kinetics (tumor growth rate), patterns of disease recurrence, locoregional control rates, and diseasespecific survival data are not available and would add much desired nuance to our findings. Lack of central pathology review raises the specter of misattribution of diagnosis for rare tumors; and it is conceivable that patients with more extended survival could have had a more differentiated carcinoma or differentiated components, because they can have a more favorable prognosis that patients with "pure" ATC. 26 In addition, survivorship bias could contribute to the magnitude of the observed outcome effect in those who received higher RT doses.
However, given the sparse numerical prevalence of ATC, single-institution reports of such limited power to render conclusions, if not suspect in terms of statistical validity, at least preclude ready generalization outside of the treating institution. Multicenter studies and populationbased data sets like the NCDB represent a cost-effective, readily available mechanism with which to characterize patterns of care and outcomes for such rare malignancies. That said, and despite attempts to control for inherent biases using propensity matching, our results should be considered hypothesis-generating and indicative, rather than definitive, in scope.
Clearly, more effective therapies for ATC are needed, and treatment on clinical trials at centers with multidisciplinary expertise should be prioritized. Several targeted agents and immunotherapies are being investigated in ATC, but how to integrate these with local therapies is yet to be defined. 27 Durable local tumor control may become even more important if systemic therapy for the treatment of distant metastatic disease becomes more effective, because we are still likely on the proximal end of the local therapy benefit curve described by Punglia et al. 28 With the ultimate goal of improving patient outcomes and 1) more rapidly identifying and evaluating patients who have localized and potentially resectable tumors for upfront surgery, 2) initiating timely nonsurgical therapies for the remaining patients who have unresectable or distant disease, and 3) prioritizing palliation and symptom support for those who are medically unfit for cancer-directed treatment, we have initiated a fasttrack program at our institution for patients with (or suspected to have) ATC. 29 On the basis of our institutional experience, current clinical guidelines, and the supportive findings from this and other retrospective analyses, we continue to consider upfront locoregional therapy incorporating higher dose neck RT for patients who have localized disease at presentation and for select fit patients who have smaller volume distant metastatic disease. 30 
Conclusion
Higher therapeutic doses of RT were associated with improved survival for patients with unresected/unresectable ATC in the NCDB database. Overall survival was poor, as anticipated, and more effective systemic and local therapies are urgently needed. Although the use of RT was relatively low in this cohort, these results highlight the importance of ensuring patients are evaluated by multidisciplinary teams that include radiation oncologists to identify more patients with ATC who may still yet benefit from combined-modality locoregional treatment, particularly regimens incorporating higher dose neck RT.
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